An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Adesis Announces Linda Choi MacDonald as New Chief Operating Officer
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Universal Display Corporation (NASDAQ:OLED) announced the appointment of Linda Choi MacDonald as Chief Operating Officer of its subsidiary, Adesis, Inc. MacDonald brings over 25 years of biopharmaceutical experience, having previously served as COO at Avanir Pharmaceuticals and held key roles at UCB Biopharma and Eli Lilly. In her new role, she will oversee Adesis' P&L, operations, and strategy. The company specializes in organic chemistry services, supporting various industries including biotech and pharmaceuticals.
Positive
Appointment of Linda Choi MacDonald as COO, expected to enhance operational expertise.
MacDonald's extensive background in biopharmaceuticals may drive growth and innovation at Adesis.
Negative
None.
NEW CASTLE, Del.--(BUSINESS WIRE)--
Adesis, Inc., a leading contract research organization and a wholly-owned subsidiary of Universal Display Corporation (Nasdaq:OLED), today announced that Linda Choi MacDonald has joined the company as Chief Operating Officer. MacDonald brings more than 25 years of experience in the biopharmaceutical industry, including leading organizations in the Americas, Europe and Asia-Pacific regions. As COO, MacDonald is responsible for overseeing Adesis’ P&L, operations and strategy.
Linda Choi MacDonald, COO of Adesis, Inc. (Photo: Business Wire)
“I am delighted to welcome Linda to Adesis,” said Andrew Cottone, Ph.D., President of Adesis, Inc. “Adding Linda’s breadth of commercial, R&D and G&A experience and her international background in the biopharmaceutical industry to our extraordinary chemistry and leadership teams is expected to expand our expertise as a world-class CRO.”
“Vitalizing people and achieving pioneering results are principles I share with Adesis,” said Linda Choi MacDonald. “I am excited to work with the Adesis team on the innovative strategies and disciplined execution that advance our customers’ ideas to market faster.”
Prior to joining Adesis, MacDonald served as Chief Operations Officer at Avanir Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical. Previously, she was Vice President of Global Marketing & Patient Access Operations, Vice President of Talent Services Asia Pacific, and Head of Global Customer-Facing Excellence Strategy & Operations at UCB Biopharma, and held various positions of increasing responsibility at Eli Lilly and Company across its commercial organizations. Her track record of success led her to be recognized as a 2020 HBA (Healthcare Businesswomen's Association) Luminary Award recipient for being a “shining example of transformational leadership.”
About Adesis, Inc.
As a wholly-owned subsidiary of Universal Display Corporation, Adesis is a contract research organization (CRO) supporting the pharma, biotech, catalysis and a number of other industries. The CRO specializes in organic and organometallic synthesis, in milligrams to multi-kilogram quantities. Adesis has a business model of providing clients with organic chemistry services in three areas: early stage research, scale up and development, and specialty manufacturing. With over 20 years of success and approximately 100 chemists with extensive industry and professional experience, Adesis supports companies in various industries with small molecule organic chemistry expertise. Adesis provides a range of services that can supplement research and development efforts. It can also act as a specialty manufacturer to reinforce supply chains and protect sensitive intellectual property. To learn more about Adesis, please visit http://adesisinc.com/.
About Universal Display Corporation
Universal Display Corporation (Nasdaq: OLED) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. To learn more about Universal Display Corporation, please visit https://oled.com.
Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other company, brand or product names may be trademarks or registered trademarks.
All statements in this document that are not historical, such as those relating to the Company’s technologies and potential applications of those technologies, the Company’s expected results and future declaration of dividends, as well as the growth of the OLED and CRO market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s Annual Report on Form 10-K for the year ended December 31, 2020. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.
Who is the new COO of Universal Display Corporation's subsidiary, Adesis?
Linda Choi MacDonald has been appointed as the new COO of Adesis, a subsidiary of Universal Display Corporation (NASDAQ:OLED).
What experience does Linda Choi MacDonald bring to Adesis?
Linda Choi MacDonald brings over 25 years of experience in the biopharmaceutical industry, including leadership positions at Avanir Pharmaceuticals and UCB Biopharma.
What is the role of Linda Choi MacDonald at Adesis?
As COO, she will oversee Adesis' P&L, operations, and strategy.
What services does Adesis provide?
Adesis specializes in organic chemistry services for various industries, including pharmaceuticals and biotech.
What is the stock symbol for Universal Display Corporation?
The stock symbol for Universal Display Corporation is OLED.
